This content is machine translated Prurigo and PN Anti-inflammatory antipruritic therapy improves quality of life Which mediators are causally involved in peripheral and central itch sensitization in the context of prurigo and prurigo nodularis (PN) and contribute to the maintenance of pruritus is currently being...…
View Post 6 min This content is machine translated Atopic dermatitis: proven therapeutic principles and innovations From healthcare research to precision medicine In Switzerland, around 20 percent of children are affected by atopic eczema, compared to 4-5 percent of adults. The disease burden of AD is considerable, which is also related to...…
View Post 6 min This content is machine translated Chronic pruritus: “Tour d'horizon” Focus on new anti-inflammatory therapeutic approaches Chronic pruritus is associated with considerable suffering and can occur both as part of classic dermatoses and as a leading symptom of many internal diseases. In chronic prurigo, long-lasting itching...…
View Post 4 min This content is machine translated Biologics for atopic dermatitis Th2 cytokines in focus: proven and new targets The range of antibody therapies for atopic dermatitis (AD) has expanded once again in Europe. In addition to dupilumab and tralokinumab, lebrikizumab is another biologic available in this country that...…
View Post 6 min This content is machine translated Atopic dermatitis Biologics and JAK-i – the best of both worlds In Switzerland, both the currently approved monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and the Janus kinase (JAK) inhibitors (baricitinib, abro-citinib, upadacitinib) can be used as “first-line” systemic therapy for patients with...…
View Post 3 min This content is machine translated COPD therapy Package of measures to combat symptom complexes – an update In COPD, dual bronchodilation (LAMA/LABA) is generally considered the standard of care. If patients are prone to exacerbations, the addition of inhaled steroids (ICS) may be useful. But what about...…
View Post 4 min This content is machine translated Asthma: focus on type 2 inflammation Remission as a new therapeutic goal A paradigm shift is emerging in the management of asthma, where the aim is not only asthma control but also remission. It has been shown that this ambitious goal can...…
View Post 9 min This content is machine translated Journal Club: Atopic dermatitis Modern systems therapy – status quo and prospects The therapeutic landscape for atopic dermatitis is changing. New findings have made it possible to develop modern treatment options that selectively target inflammatory signaling pathways. There are currently two modern…
View Post 6 min This content is machine translated Chronic prurigo Antipruritic therapy alleviates suffering Chronic prurigo is associated with persistent papules and nodules on the skin and is now defined as a disease in its own right. However, this was not always the case:…
View Post 7 min This content is machine translated Biologics for AD Interleukin-13 as a target – new long-term data available Now that the range of systemic therapeutics for atopic dermatitis has been expanded and the two monoclonal antibodies dupilumab and tralokinumab as well as three Janus kinase inhibitors have been…
View Post 4 min This content is machine translated Dupilumab for COPD and asthma Exacerbations reduced and lung function improved The monoclonal antibody dupilumab blocks the common receptor component for interleukin (IL)-4 and IL-13, the central drivers of type 2 inflammation. It has been approved in Switzerland since 2019, and…
